Serum homocysteine and long-term risk of myocardial infarction and sudden death in patients with coronary heart disease

Cardiology

Volumn 107, Issue 1, 2006, Pages 52-56

  Haim, Moti ^a,c   Tanne, David ^b,c   Goldbourt, Uri ^b,c   Doolman, Ram ^b,c   Boyko, Valentina ^b,c   Brunner, Daniel ^c   Sela, Ben Ami ^b,c   Behar, Solomon ^b,c  

^a RABIN MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Homocysteine; Myocardial infarction; Risk factors

Indexed keywords

BEZAFIBRATE; HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREVENTION STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUDDEN DEATH;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CASE-CONTROL STUDIES; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33750993264     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093697     Document Type: Article

References (30)

1. Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-1050.
2. Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, Hooper J, Turner RM, Thompson SG, Kooner JS: Plasma homocysteine concentrations and risk of coronary heart disease in UK, Indian, Asian, and European men. Lancet 2000;355:523-527.
3. Joubran R, Asmi M, Busjahn A, Vergopoulos A, Luft FC, Jouma M: Homocysteine levels and coronary heart disease in Syria. J Cardiovasc Risk 1998;5:257-261.
4. Nikkari ST, Kalela A, Koivu TA, Koivula T, Alho H, Jokela H, Sillanaukee P: Serum homocysteine does not associate with uncomplicated coronary heart disease. Eur J Clin Invest 2001;31:581-585.
5. Ridker PM, Shih J, Cook TJ, Clearfield M, Downs JR, Pradhan AD, Weis SE, Gotto AM Jr: Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation 2002;105:1776-1779.
6. Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L, Thomson A, Ueland PM, Ebrahim SB: Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart 1999;82:448-454.
7. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM: Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-867.
8. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE: Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-709.
9. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992;268:877-881.
10. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM: Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002:105:2595-2599.
11. Fallon UB, Ben-Shlomo Y, Elwood P, Ubbink JB, Smith GD: Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up. Heart 2001;85:153-158.
12. Voutilainen S, Lakka TA, Hamelahti P, Lehtimaki T, Poulsen HE, Salonen JT: Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio ischaemic heart disease risk factor study. J Intern Med 2000;248:217-222.
13. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH: Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol 1997;17:1947-1953.
14. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH: Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Indian Heart J 2000;52:S44-S52.
15. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 2000;321:199-204.
16. Knekt P, Reunanen A, Alfthan G, Heliovaara M, Rissanen H, Marniemi J, Aromaa A: Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease? Arch Intern Med 2001;161:1589-1594.
17. Knekt P, Alfthan G, Aromaa A, Heliovaara M, Marniemi J, Rissanen H, Reunanen A: Homocysteine and major coronary events: a prospective population study amongst women. J Intern Med 2001;249:461-465.
18. Berliner S, Rogowski O, Rotstein R, Fusman R, Shapira I, Bornstein NM, Prochorov V, Roth A, Keren G, Eldor A, Zeltser DL: Activated polymorphonuclear leukocytes and monocytes in the peripheral blood of patients with ischemic heart and brain conditions correspond to the presence of multiple risk factors for atherothrombosis. Cardiology 2000;94:19-25.
19. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, Ji J, Otto JM, Taylor LM Jr: Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 1994;40:873-881.
20. Haim M, Tanne D, Boyko V, Reshef T, Goldbourt U, Leor J, Mekori YA, Behar S: Soluble intercellular adhesion molecule-1 and longterm risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. J Am Coll Cardiol 2002;39:1133-1138.
21. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U: Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol 1996;16:351-356.
22. Ridker PM, Shih J, Cook TJ, Clearfield M, Downs JR, Pradhan AD, Weis SE, Gotto AM Jr, for the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex-CAPS) Investigators: Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation 2002;105:1776-1779.
23. Chambers JC, Kooner JS: Homocysteine: a novel risk factor for coronary heart disease in UK Indian Asians. Heart 2001;86:121-122.
24. Rothenbacher D, Fischer HG, Hoffmeister A, Hoffmann MM, Marz W, Bode G, Rosenthal J, Koenig W, Brenner H: Homocysteine and methylenetetrahydrofolate reductase genotype: association with risk of coronary heart disease and relation to inflammatory, hemostatic, and lipid parameters. Atherosclerosis 2002;162:193-200.
25. Danesh J, Lewington S: Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998;5:229-232.
26. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB: Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 2002;31:59-70.
27. Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D: Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 1998;18:1895-1901.
28. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, Pearson RR: Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000;102:1227-1232.
29. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236.
30. Tribouilloy CM, Peltier M, Iannetta Peltier MC, Trojette F, Andrejak M, Lesbre JP: Plasma homocysteine and severity of thoracic aortic atherosclerosis. Chest 2000;118:1685-1689.